Circulatory syndrome: An evolution of the metabolic syndrome concept!

Current Cardiology Reviews

Volumn 8, Issue 1, 2012, Pages 68-76

  Khoshdel, Ali Reza ^a,b,c   Carney, Shane L ^b   Gillies, Alastair ^b  

^a AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c NONE   (Iran)

Author keywords

Anaemia; Arterial stiffness; Circulatory system; Metabolic syndrome; Renal function; Ventricular function

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGING; ANEMIA; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIRCULATORY SYNDROME; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DIET; DIET RESTRICTION; DYSLIPIDEMIA; ENDOTHELIUM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART INFARCTION; HEART VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INFLAMMATION; KIDNEY DYSFUNCTION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK ASSESSMENT; SEDENTARY LIFESTYLE; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84870171347     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340312801215773     Document Type: Article

References (141)

1. Stedman's Medical Dictionary. 27th edition ed. 2000, Baltimore: Lippincott, Williams and Wilkins. p.1746.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988. 37(12): p. 1595-607.
3. Ormezzano O, JP Baguet, P Francois, et al. Is there any real target organ damage associated with white-coat normotension? Clin Auton Res 2004; 14(3): p. 160-6.
4. Balkau B and MA Charles. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16(5): p. 442-3.
5. Einhorn D, GM Reaven, RH Cobin, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3): p. 237-52.
6. Grundy SM, HB Brewer, Jr, JI Cleeman, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): p. 433-8.
7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001; 285(19): p. 2486-97.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): p. 3143-421.
9. Alexander CM, PB Landsman, SM Teutsch, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52(5): p. 1210-4.
10. Athyros VG, ES Ganotakis, MS Elisaf, et al. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2006.
11. Kahn R, J Buse, E Ferrannini, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9): p. 2289-304.
12. Malik S, ND Wong, SS Franklin, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): p. 1245-50.
13. Girman CJ, T Rhodes, M Mercuri, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93(2): p. 136-41.
14. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173(2): p. 309-14.
15. Hunt KJ, RG Resendez, K Williams, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110(10): p. 1251-7.
16. Scuteri A, SS Najjar, CH Morrell, et al. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005; 28(4): p. 882-7.
17. Cameron A. The metabolic syndrome: Validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 2010; 65: p. 117-21.
18. Ford ES, MB Schulze, T Pischon, et al. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovascular Diabetology 2008; 7(35). p. doi: 10.1186/1475-2840-7-35.
19. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33(2): p. 283-303.
20. Robbins DC, L Andersen, R Bowsher, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes 1996; 45(2): p. 242-56.
21. Wallace TM, JC Levy and DR Matthews. Use and abuse of HOMA modeling. Diabetes Care 2004; 27(6): p. 1487-95.
22. Liao Y, S Kwon, S Shaughnessy, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27(4): p. 978-83.
23. Bruno G, F Merletti, A Biggeri, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27(11): p. 2689-94.
24. Resnick HE, K Jones, G Ruotolo, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 2003; 26(3): p. 861-7.
25. Marroquin OC, KE Kip, DE Kelley, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109(6): p. 714-21.
26. Lakka HM, DE Laaksonen, TA Lakka, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. Jama 2002; 288(21): p. 2709-16.
27. Grundy SM, JI Cleeman, SR Daniels, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): p. 2735-52.
28. Amar J, JB Ruidavets, B Chamontin, et al. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001; 19(3): p. 381-7.
29. Asmar R, A Rudnichi, J Blacher, et al. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive population. Am J Hypertension 2001; 14: p. 91-7.
30. Blacher J, ME Safar, AP Guerin, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney international 2003; 63: p. 1852-60.
31. Boutouyrie P, AI Tropeano, R Asmar, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. Hypertension 2002; 39: p. 10-15.
32. London GM and JN Cohn. Prognostic application of arterial stiffness: task forces. Am J Hypertens 2002; 15(8): p. 754-8.
33. Laurent S, J Cockcroft, L Van Bortel, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27(21): p. 2588-605.
34. Mourad A, A Khoshdel, S Carney, et al. Haemodialysisunresponsive blood pressure: cardiovascular mortality predictor? Nephrology (Carlton) 2005; 10(5): p. 438-41.
35. Khoshdel AR, SL Carney, P Trevillian, et al. Evaluation of arterial stiffness and pulse wave reflection for cardiovascular risk assessment in diabetic and nondiabetic kidney transplant recipients. Iran J Kidney Dis 2010; 4(3): p. 237-43.
36. Khoshdel AR and SL Carney. HEMODYNAMIC RESPONSE TO EXERCISE PREDICTS THE DEVELOPMENT OF SEVERE RENAL FAILURE. in 14th World Congress on Heart Disease 2008; Toronto, CANADA, July 2008; American Heart Association.
37. Khoshdel AR, SL Carney and S White. Disturbed hemodynamic cardiac exercise stress test response in non-smoking, normolipidemic, normotensive, diabetic subjects. Diabetes Res Clin Pract 2007; 75(2): p. 193-9.
38. Khoshdel AR, SL Carney, BR Nair, et al. Better management of cardiovascular diseases by pulse wave velocity: combining clinical practice with clinical research using evidence-based medicine. Clin Med Res 2007; 5(1): p. 45-52.
39. Khoshdel AR, A Thakkinstian, SL Carney, et al. Estimation of an age-specific reference interval for pulse wave velocity: a metaanalysis. J Hypertens 2006; 24(7): p. 1231-7.
40. Khoshdel AR, SL Carney, A Gillies, et al. The impact of diabetes mellitus on arterial stiffness in end-stage renal disease (Abstract). Nephrology 2005; 10(Supplement): p. A21.
41. Khoshdel AR. Metabolic syndrome: Erasing the problem or constructing a better answer. BMJ rapid response at www.bmj.com, 2008. 27th March 2008.
42. Knudsen ST, PL Poulsen, KW Hansen, et al. Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. Am J Hypertens 2002; 15(3): p. 244-50.
43. Thomas MC, RJ MacIsaac, C Tsalamandris, et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2004; 89(9): p. 4359-63.
44. Eckel RH, SM Grundy and PZ Zimmet. The metabolic syndrome. Lancet 2005; 365(9468): p. 1415-28.
45. Bongartz LG, MJ Cramer, PA Doevendans, et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26(1): p. 11-7.
46. Becker B, F Kronenberg, JT Kielstein, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16(4): p. 1091-8.
47. Saydah SH, J Fradkin and CC Cowie. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Jama 2004; 291(3): p. 335-42.
48. Fox CS, MG Larson, EP Leip, et al. Predictors of new-onset kidney disease in a community-based population. Jama, 2004; 291(7): p. 844-50.
49. Amann K, C Wanner and E. Ritz. Cross-Talk between the Kidney and the Cardiovascular System. J Am Soc Nephrol 2006; 17(8): p. 2112-9.
50. Mattu RK, J Trevelyan, EW Needham, et al. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetes. Diabetologia 2002; 45(6): p. 905-13.
51. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002; 17 Suppl 11: p. 50-4.
52. Locatelli F, J Bommer, GM London, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16(3): p. 459-68.
53. Colhoun HM, DJ Betteridge, PN Durrington, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): p. 685-96.
54. Geluk CA, FW Asselbergs, HL Hillege, et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 2005; 26(13): p. 1314-20.
55. Sola S, MQ Mir, S Lerakis, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47(2): p. 332-7.
56. Elisaf M and DP Mikhailidis. Statins and renal function. Angiology 2002; 53(5): p. 493-502.
57. Dogra GK, GF Watts, DC Chan, et al. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet Med 2005; 22(3): p. 239-42.
58. Bakker SJ, RT Gansevoort and D de Zeeuw. Metabolic syndrome: a fata morgana? Nephrol Dial Transplant 2007; 22(1): p. 15-20.
59. Global Health Risks: Morbidity and burden of disease attributable to selected major risks. WHO Global Reports 2009; 70.
60. Zandi-Nejad K, VA Luyckx and BM Brenner. Adult hypertension and kidney disease: the role of fetal programming. Hypertension 2006; 47(3): p. 502-8.
61. Vlachopoulos C and M O'Rourke. Genesis of the normal and abnormal arterial pulse. Curr Probl Cardiol 2000; 25(5): p. 303-67.
62. Fuenmayor N, E Moreira and LX Cubeddu. Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens 1998; 11(4 Pt 1): p. 397-402.
63. Sharma AM, U Schorr and A Distler. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 1993; 21(3): p. 273-9.
64. Weir MR. Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Miner Electrolyte Metab 1998; 24(6): p. 438-45.
65. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of syndrome X. Am J Hypertens 1993; 6(4): p. 123S-134S.
66. Cohn JN, AA Quyyumi, NK Hollenberg, et al. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004; 109(25 Suppl 1): p. IV31-46.
67. Kimoto E, T Shoji, K Shinohara, et al. Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 2003; 52(2): p. 448-52.
68. Hopkins KD, ED Lehmann, RL Jones, et al. A family history of NIDDM is associated with decreased aortic distensibility in normal healthy young adult subjects. Diabetes Care 1996; 19(5): p. 501-3.
69. Ratto E, G Leoncini, F Viazzi, et al. Ambulatory arterial stiffness index and renal abnormalities in primary hypertension. J Hypertens 2006; 24(10): p. 2033-8.
70. Pirro M, G Schillaci, G Savarese, et al. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 2004; 34(5): p. 335-41.
71. Wilkinson I and JR Cockcroft. Cholesterol, lipids and arterial stiffness. Adv Cardiol 2007; 44: p. 261-77.
72. Mottram PM, BA Haluska, R Leano, et al. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart 2005; 91(12): p. 1551-6.
73. Gates PE, H Tanaka, J Graves, et al. Left ventricular structure and diastolic function with human ageing. Relation to habitual exercise and arterial stiffness. Eur Heart J 2003; 24(24): p. 2213-20.
74. Ritz E. Heart and kidney: fatal twins? Am J Med 2006; 119(5 Suppl 1): p. S31-9.
75. Cruickshank K, L Riste, SG Anderson, et al. Aortic Pulse-Wave Velocity and its relationship to Mortality in Diabetes and Glucose intolerance. Circulation 2002; 106: p. 2085-90.
76. Laurent S, P Boutouyrie, R Asmar, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: p. 1236-41.
77. London GM, J Blacher, B Pannier, et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38(3): p. 434-8.
78. Meaume S, A Rudnichi, A Lynch, et al. Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years old. J Hypertens 2001; 19(5): p. 871-7.
79. Yokoyama H, M Kuramitsu, S Kanno, et al. Relationship between metabolic syndrome components and vascular properties in Japanese type 2 diabetic patients without cardiovascular disease or nephropathy. Diabetes Res Clin Pract 2006.
80. Cerasola G, S Cottone, G Mule, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14(7): p. 915-20.
81. Cruickshank K, L Riste, SG Anderson, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106(16): p. 2085-90.
82. Niskanen L, M Uusitupa, H Sarlund, et al. Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1990; 33(4): p. 237-43.
83. Smith A, J Karalliedde, L De Angelis, et al. Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16(4): p. 1069-75.
84. Kohara K, Y Tabara, R Tachibana, et al. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res 2004; 27(7): p. 471-7.
85. Peppa-Patrikiou M, M Dracopoulou and C Dacou-Voutetakis. Urinary endothelin in adolescents and young adults with insulindependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors. Metabolism 1998; 47(11): p. 1408-12.
86. Pedrinelli R, G Dell'Omo, V Di Bello, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24(12): p. 2414-9.
87. Aso Y, N Yoshida, K Okumura, et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004; 348(1-2): p. 139-45.
88. Kelbaek H, T Jensen, B Feldt-Rasmussen, et al. Impaired leftventricular function in insulin-dependent diabetic patients with increased urinary albumin excretion. Scand J Clin Lab Invest 1991; 51(5): p. 467-73.
89. Estacio RO, JG Regensteiner, EE Wolfel, et al. The association between diabetic complications and exercise capacity in NIDDM patients. Diabetes Care 1998; 21(2): p. 291-5.
90. Peralta CA, M Kurella, JC Lo, et al. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15(4): p. 361-5.
91. Magri P, MA Rao, S Cangianiello, et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 1998; 98(25): p. 2849-54.
92. Sarafidis PA and LM Ruilope. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006; 26(3): p. 232-44.
93. Ruilope, L.M, D.J. van Veldhuisen, E. Ritz, et al. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol, 2001. 38(7): p. 1782-7.
94. Safar ME, GM London and GE Plante. Arterial stiffness and kidney function. Hypertension 2004; 43(2): p. 163-8.
95. Zoccali C, R Maio, G Tripepi, et al. Inflammation as a mediator of the link between mild to moderate renal insufficiency and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17(4 Suppl 2): p. S64-8.
96. Levine DZ. Hyperfiltration, nitric oxide, and diabetic nephropathy. Curr Hypertens Rep 2006; 8(2): p. 153-7.
97. Palatini P, P Mormino, F Dorigatti, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006; 70(3): p. 578-84.
98. Weiss G and LT Goodnough. Anemia of chronic disease. N Engl J Med 2005; 352(10): p. 1011-23.
99. Srivastava PM, MC Thomas, P Calafiore, et al. Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond) 2006; 110(1): p. 109-16.
100. Smith KJ, AJ Bleyer, WC Little, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59(3): p. 538-48.
101. Ritz E. Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant 2005; 20 Suppl 6: p. vi21-5.
102. Kovesdy CP, BK Trivedi, K Kalantar-Zadeh, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69(3): p. 560-4.
103. Streeter RP and D Mancini. Treatment of anemia in the patient with heart failure. Curr Treat Options Cardiovasc Med 2005; 7(4): p. 327-32.
104. Katzmarzyk PT, TS Church and SN Blair. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004; 164(10): p. 1092-7.
105. Jouven X, JP Empana, PJ Schwartz, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352(19): p. 1951-8.
106. Williams SG, M Jackson, LL Ng, et al. Exercise duration and peak systolic blood pressure are predictive of mortality in ambulatory patients with mild-moderate chronic heart failure. Cardiology 2005; 104(4): p. 221-6.
107. Bonapace S, A Rossi, M Cicoira, et al. Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathy. Circulation 2003; 107(12): p. 1603-8.
108. Boyer JK, S Thanigaraj, KB Schechtman, et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004; 93(7): p. 870-5.
109. Vinereanu D, E Nicolaides, AC Tweddel, et al. Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci (Lond) 2003; 105(5): p. 591-9.
110. McMahon AC, RU Naqvi, MJ Hurst, et al. Diastolic dysfunction and abnormality of the Na+/Ca2+ exchanger in single uremic cardiac myocytes. Kidney Int 2006; 69(5): p. 846-51.
111. Ando K and T Fujita. Anti-diabetic effect of blockade of the reninangiotensin system. Diabetes Obes Metab 2006; 8(4): p. 396-403.
112. Derosa G, AF Cicero, A Dangelo, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28(11): p. 917-24.
113. Raji A and J Plutzky. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep 2002; 4(6): p. 514-21.
114. Undas A, KE Brummel-Ziedins and KG Mann. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25(2): p. 287-94.
115. Fliser D, K Buchholz and H Haller. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110(9): p. 1103-7.
116. Gross ML, K Amann and E Ritz. Nephron number and renal risk in hypertension and diabetes. J Am Soc Nephrol 2005; 16 Suppl 1: p. S27-9.
117. Hobson A, PA Kalra and PR Kalra. Cardiology and nephrology: time for a more integrated approach to patient care? Eur Heart J 2005; 26(16): p. 1576-8.
118. Lee YJ and JC Tsai. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care 2002; 25(6): p. 1002-8.
119. Zozulinska D and B Wierusz-Wysocka. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract 2006.
120. Li JJ, CH Fang and RT Hui. Is hypertension an inflammatory disease? Med Hypotheses 2005; 64(2): p. 236-40.
121. Li JJ and JL Chen. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005; 64(5): p. 925-9.
122. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169(2): p. 203-214.
123. Shoelson SE, J Lee and AB Goldfine. Inflammation and insulin resistance. J Clin Invest 2006; 116(7): p. 1793-801.
124. Stuveling EM, SJ Bakker, HL Hillege, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004; 43(4): p. 791-6.
125. Ridker PM, PW Wilson and SM Grundy. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109(23): p. 2818-25.
126. Stehouwer CD, MA Gall, JW Twisk, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51(4): p. 1157-65.
127. Palmieri V, RP Tracy, MJ Roman, et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003; 26(10): p. 2764-9.
128. Ridker PM, N Rifai, NR Cook, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. Jama 2005; 294(3): p. 326-33.
129. Sagastagoitia JD, Y Saez, M Vacas, et al. Association between inflammation, lipid and hemostatic factors in patients with stable angina. Thromb Res 2006.
130. Devaraj S, RS Rosenson and I Jialal. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33(2): p. 431-53. table of contents.
131. Matteucci E, J Rosada, M Pinelli, et al. Systolic blood pressure response to exercise in type 1 diabetes families compared with healthy control individuals. J Hypertens 2006; 24(9): p. 1745-51.
132. Keung YK and J Owen. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost 2004; 10(4): p. 387-91.
133. Nieuwdorp M, ES Stroes, JC Meijers, et al. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005; 5(2): p. 155-9.
134. Sechi LA, L Zingaro, C Catena, et al. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000; 36(6): p. 978-85.
135. Danesh J, S Lewington, SG Thompson, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Jama 2005; 294(14): p. 1799-809.
136. Marcucci R, AM Gori, F Giannotti, et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4(5): p. 1017-22.
137. Vicari AM, MV Taglietti, F Pellegatta, et al. Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure. A possible link to increased cardiovascular mortality? Diabetes Care 1996; 19(10): p. 1062-6.
138. Haffner SM, L Mykkanen, A Festa, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulinsensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101(9): p. 975-80.
139. Isomaa B, P Almgren, T Tuomi, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(4): p. 683-9.
140. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease. Diabetes Care 2006; 29(8): p. 1973-80.
141. Juhan-Vague I, MC Alessi, A Mavri, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1(7): p. 1575-9